Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.

Keywords: binding antibodies; BNT162b2; Comirnaty; COVID-19; immunoassays; immunological response; kinetics; neutralizing antibodies; SARS-CoV-2 vaccine; serology EN binding antibodies BNT162b2 Comirnaty COVID-19 immunoassays immunological response kinetics neutralizing antibodies SARS-CoV-2 vaccine serology 456 463 8 02/07/22 20220201 NES 220201 Introduction The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) continues to sustain a global public health crisis, despite the availability of vaccines that have dramatically reduced severe disease, hospitalization and mortality [[1]]. However, the decrease in serum antibodies against SARS-CoV-2 have raised questions concerning long-term immunity, since decreased antibody levels have been associated with breakthrough infections, prompting the consideration of additional vaccine booster doses [[4]]. The waning of serum antibodies and neutralizing antibodies against SARS-CoV-2 has been widely documented [[16]], although several studies have underlined that levels of vaccine-induced Ab persist also 6 months after the second dose [[18]]. [Extracted from the article]